

# Study of Canakinumab in Patients With Myelofibrosis

NCT05467800

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	John Mascarenhas
<b>Enrollment</b>	14 participants

## Key Eligibility Criteria

---

### Inclusion (28)

- The following are required for inclusion in the study:
- Parts 1 and 2:
- Participants must voluntarily sign informed consent form (ICF) and be willing and able to adhere to the study visit schedule and all protocol requirements.
- Participants must be ≥ 18 years of age at the time of signing the ICF.
- Participants must have a pathologically confirmed diagnosis of PMF as per the World Health Organization (WHO) diagnostic criteria<sup>46</sup> or post-ET MF or post-PV MF according to IWG-MRT criteria.<sup>47</sup>

... and 23 more (see full listing online)

### Exclusion (18)

- Any of the following is a criterion for exclusion from the study:
- Prior malignancy active within the previous 1 year except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
- Any of the following cardiac abnormalities
- Uncontrolled, symptomatic congestive heart failure as designated by the treating physician
- Myocardial infarction 6 months prior to enrollment

... and 13 more (see full listing online)

## Locations (8 total)

---

Mayo Clinic Arizona, Phoenix, Arizona, United States

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

Moffitt Cancer Center, Tampa, Florida, United States

... and 5 more locations